Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Simplified antiviral NVP

<< Previous

Bullboard Posts

Next >>

Comment by forhandlarenon Dec 21, 2021 3:21am

246 Views

Post# 34249321

RE:Simplified antiviral NVP

I have adjusted the model in two ways.

CAGR of 28 percent for 15 years is too optimistic.

Year 01-05 : 28 percent
Year 06-10 : 08 percent
Year 11-15 : 04 percent

Seems like an disruptive scientific approach. Peak sales is more likely 20 percent.

NPV is CAD 4.94 per share.

<< Previous

Bullboard Posts

Next >>

5 steps to mastering risk management in the stock market